TRIO and myxofibrosarcoma: This study provides evidence that integrin α10 subunit may control growth and metastasis development in myxofibrosarcoma, and targeting integrin α10/TRIO/RICTOR pathway with EHop-016 and INK128 inhibitors could be clinically beneficial for myxofibrosarcoma patients.